Cinctive Capital Management’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-330,000
Closed -$33.5M 419
2025
Q4
$33.5M Buy
330,000
+307,386
+1,359% +$24.7M 1.81% 5
2025
Q3
$1.24M Buy
+22,614
New +$1.13M 0.06% 287
2025
Q1
Sell
-112,351
Closed -$6.31M 365
2024
Q4
$6.31M Buy
112,351
+103,841
+1,220% +$6.46M 0.32% 104
2024
Q3
$580K Buy
+8,510
New +$480K 0.03% 332
2024
Q2
Sell
-9,685
Closed -$669K 432
2024
Q1
$669K Buy
+9,685
New +$613K 0.03% 321
2023
Q4
Sell
-59,802
Closed -$4.08M 407
2023
Q3
$4.08M Buy
+59,802
New +$5.07M 0.2% 156
2023
Q1
Sell
-35,416
Closed -$1.75M 450
2022
Q4
$1.75M Buy
+35,416
New +$1.45M 0.09% 275
2021
Q2
Sell
-39,012
Closed -$5.14M 537
2021
Q1
$5.14M Sell
39,012
-28,382
-42% -$3.89M 0.31% 115
2020
Q4
$8.93M Buy
67,394
+16,221
+32% +$1.96M 0.73% 25
2020
Q3
$5.22M Buy
+51,173
New +$4.42M 0.46% 72

Other funds holding EXAS

Cinctive Capital Management's EXAS Position: Q1 2026 in Review

Cinctive Capital Management sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 330,000 shares — an estimated $33.5M sold.

Cinctive Capital Management first reported a position in EXAS in Q3 2020 and held it in 10 quarters. The position peaked at $33.5M in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Cinctive Capital Management reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Cinctive Capital Management sold 330,000 Exact Sciences shares in Q1 2026, an estimated $33.5M.
  • Cinctive Capital Management first reported a position in Exact Sciences in Q3 2020 and held it in 10 quarters.
  • Cinctive Capital Management's Exact Sciences position peaked at $33.5M in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Cinctive Capital Management's 13F filing for Q1 2026, filed 15 May 2026.